Severe acute pancreatitis (AP) is a pathology with high morbidity and mortality. Portosplenomesenteric vein thrombosis is a well-known local complication of AP with a variable incidence, which can reach up to 50% in case of severe AP. However, there is no specific recommendation regarding the management of Portosplenomesenteric vein thrombosis. By analogy to all venous thrombosis, the European Society of Gastroenterology recommends curative anticoagulation. However, the efficacy of curative anticoagulation has never been evaluated by prospective studies. In addition, bleeding complications during AP occur in approximately 10% of patients and are associated with a poor prognosis. The investigators wish to conduct an observational multi-center study with epidemiologic aims, including all patients admitted for AP and with a diagnosis of portosplenomesenteric vein thrombosis. The aim of this study is to evaluate the therapeutic management of these patients, the efficacy and safety of anticoagulant treatment for the treatment of Portosplenomesenteric vein thrombosis, and their outcomes.
The investigators will include prospectively all patients admitted for AP with a computed tomography diagnosis of portosplenomesenteric vein thrombosis.
Study Type
OBSERVATIONAL
Enrollment
51
patients admitted for AP with portosplenomesenteric vein thrombosis.
CHU de Nantes
Nantes, France
incidence of anticoagulation therapy
incidence defined as : the ratio of the number of patients on curative anticoagulant therapy to the number of patients admitted with AP and portosplenomesenteric vein thrombosis during the inclusion period
Time frame: up to 12 months
evaluate the outcomes of Number of patients admitted for AP with portosplenomesenteric vein thrombosis
Time frame: up to 12 months
hospital mortality at D28
evaluate the hospitality mortality at D28 of patients admitted for AP with portosplenomesenteric vein
Time frame: Day 28
hospital mortality at D90
evaluate the hospitality mortality at D90 of patients admitted for AP with portosplenomesenteric vein
Time frame: Day 90
hospital mortality at 6 months
evaluate the hospitality mortality at 6 months of patients admitted for AP with portosplenomesenteric vein
Time frame: 6 months
hospital mortality at 12 months
evaluate the hospitality mortality at 12 months of patients admitted for AP with portosplenomesenteric vein
Time frame: 12 months
incidence of portal cavernoma
evaluate the incidence of portal cavernoma of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
incidence of type 2 diabetes secondary to AP
evaluate the incidence of type 2 diabetes secondary to AP of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
incidence of occurrence of malabsorption
evaluate the incidence of occurrence of malabsorption of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
incidence of digestive ischemia
evaluate the incidence of digestive ischemia of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
incidence of hepatic ischemia
evaluate the incidence of hepatic ischemia of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
incidence of pancreatic necrosis
evaluate the incidence of pancreatic necrosis of patients admitted for AP with portosplenomesenteric vein
Time frame: up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.